Clinical Trials Browser

Has results × Multiple Myeloma × belantamab mafodotin × Clear all

NCT04162210 2026-02-11

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT05064358 2025-10-07

DREAMM 14

Phase 2 Active not recruiting

177 enrolled 37 charts

Multiple Myeloma, Recurrence

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1 Completed

15 enrolled 91 charts

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT04896658 2025-04-03

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

10 enrolled 14 charts

Multiple Myeloma

NCT04177823 2025-03-20

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1 Completed

6 enrolled 48 charts

Multiple Myeloma

NCT03544281 2025-03-18

DREAMM 6

Phase 1/2 Completed

153 enrolled 91 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Multiple Myeloma

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Multiple Myeloma

NCT05117008 2025-01-28

EMBRACE

Phase 2 Terminated

1 enrolled 5 charts

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT03848845 2024-04-09

DREAMM 4

Phase 1/2 Completed

41 enrolled 57 charts

Multiple Myeloma

NCT06160609 2024-03-12

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Phase 1/2 Terminated

9 enrolled 14 charts

Multiple Myeloma

NCT04549363 2023-12-13

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Phase 3 Terminated

16 enrolled 7 charts

Multiple Myeloma

NCT02064387 2020-08-11

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

Phase 1 Completed

79 enrolled 59 charts

Multiple Myeloma